ClinicalTrials.gg
CompletedNCT00770835SPLENDORUpdated Jul 12, 2011

Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.

A Phase 4 interventional study of Pioglitazone and Metformin and Glibenclamide and Metformin in Diabetes Mellitus, sponsored by Takeda. Completed at 2 sites in Italy. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-07-12.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's title name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
97th of 122
39 · median 103
Started
2009
with 6 others
Phase 4
57 of 122
4 open now
Registered
48th of 122
by date
Lead sponsor
27 of 122
Takeda

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 97th largest by enrollment, is one of 7 that started in 2009, is one of 57 in phase 4, and was the 48th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of pioglitazone compared to glibenclamide, once daily (QD), taken together with metformin and lifestyle modification in type 2 diabetic subjects with cardiovascular disease.

Read the detailed description

Diabetes is one of the most common chronic diseases worldwide, affecting nearly 200 million people, almost all suffering from Type 2 Diabetes. It is the fourth leading cause of death in developed countries due to the negative impact of the disease on the cardiovascular system. Treatment, aimed to the reduction of this intrinsic cardiovascular risk, is based on tight control of glucose and all coexisting metabolic abnormalities as well as of biomarkers of inflammation and atherogenesis.

Macrovascular complications account for the vast majority of morbidity and mortality in diabetic patients, and there is growing evidence that pathophysiologic mechanisms other than hyperglycemia are responsible. The condition of the vascular endothelium in particular has been shown to effect the health and disease of the cardiovascular system.

The number and function of endothelial progenitor cells correlate inversely with cardiovascular risk factors and may be a surrogate biologic marker for vascular function and cumulative cardiovascular risk.

Pioglitazone is an orally active thiazolidinedione derivative. It is a ligand for peroxisome proliferator-activated receptor-gamma activation that alters transcription of various genes regulating carbohydrate and lipid metabolism.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • Glucose Metabolism Disorder
  • Dysmetabolic Syndrome
  • Type II Diabetes
  • Diabetes Mellitus, Lipoatrophic
  • Dyslipidemia
  • Drug Therapy
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 39 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be non-pregnant, non-lactating and .
  • A glycosylated level greater than 7.5% and less than 10%.
  • Has an age of onset of Type 2 Diabetes greater than 35 years of age.
  • Is on metformin monotherapy up to the maximum tolerated daily dose.
  • Has a normal or only slightly impaired renal function (a modification of diet in renal disease estimated greater than 60 ml/min/1.73m2.
  • Antihypertensives, statins and any other hypolipidemic medications have been initiated at least three months prior to enrollment; no dose modifications are allowed during the study.
  • Has one or more cardiovascular comorbidities as follows:

    • stable angina pectoris
    • previous (greater than three months) , cerebrovascular accident or carotid atherosclerosis as assessed by bilateral carotid artery ultrasonography
    • peripheral vascular complications documented by a history of claudication or rest pain, ultrasonography or angiography.
  • and/or two or more of the following major cardiovascular risk factors:

    • hypertension (blood pressure >130/80 mmHg or treatment)
    • dyslipidemia (low-density lipoprotein-cholesterol >100 mg/dl or treatment and/or high-density lipoprotein-cholesterol \<40 mg/dl in men and \<45 mg/dl in women or treatment)
    • smoking (>10 cigarettes/day)

Exclusion criteria

Exclusion Criteria:

  • Has Type 1 Diabetes.
  • Is on insulin therapy.
  • Is severely obese defined as a greater than or equal to 40mg/m2
  • Has diabetic retinopathy.
  • Has evidence of hepatic dysfunction including liver transaminase greater than three times the .
  • Is unable to remain on a stable dose of the following class of medications 30 days prior to randomization and throughout the six months of the study:

    • antihypertensives
    • statins
    • other hypolipidemic and antiplatelet drugs
  • Has a history of alcohol or other drug abuse.
  • Has had a new diagnosis of cancer or recurrent cancer within five years of screening.
  • Has a need for chronic (greater than two weeks) therapy.
  • Has had heart failure based on the Functional Class I through IV.
  • Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:

    • Other antidiabetic drugs (except metformin)
    • Fibrates
    • Rifampicin
    • Glibenclamide interacting drugs, including nonsteroidal anti-inflammatory agents
    • Other drugs that are highly protein bound, including:

      • sulphonamides
      • chloramphenicol
      • probenecid
      • monoamine oxidase inhibitors
      • fluoroquinolones antibiotics
      • oral miconazole
  • Has participated in another clinical study within the past three months.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Pioglitazone and Metformin QD

    (along with lifestyle modification)

    Drug: Pioglitazone and Metformin

  • Active comparator
    Glibenclamide and Metformin QD

    (along with lifestyle modification)

    Drug: Glibenclamide and Metformin

Interventions

  • DrugPioglitazone and Metformin

    Drug pages: Pioglitazone · Metformin

    Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.

    Also known as: ACTOS®, AD-4833

  • DrugGlibenclamide and Metformin

    Drug pages: Glyburide · Metformin

    Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.

    Also known as: Diabeta, Glynase, Micronase, Daonil, Semi-Daonil, Euglucon

07

What researchers measure

Primary outcomes

  1. Increase from Baseline in the number of Endothelial Progenitor Cells (CD34+KDR+).

    Time frame: Baseline and Final Visit.

Secondary outcomes

  1. Change from Baseline in Circulating Progenitor Cells Integrated Markers of cardiovascular risk (CD34+).

    Time frame: Baseline and Weeks 12 and 24.

  2. Change from Baseline in Flow Mediated Dilation Integrated Markers of cardiovascular risk.

    Time frame: Baseline and Final Visit.

  3. Modulation of Endothelial Progenitor Cell recruitment (vascular endothelial growth factor, erythropoietin and stromal cell-derived factor-1).

    Time frame: Weeks: 4, 12 and 24.

  4. Measure of Glucose Control (glycosylated hemoglobin and fasting plasma glucose).

    Time frame: Weeks: 4, 12 and 24.

  5. Measure of Lipid Parameters (total lipids, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein B and apolipoprotein A1).

    Time frame: Weeks: 4, 12 and 24.

  6. Change from Baseline in lipid parameters (free fatty acids and oxidized low-density lipoprotein).

    Time frame: Baseline and Weeks 12 and 24.

  7. Change from Baseline in insulin sensitivity (insulin indexes by 2 hour oral glucose tolerance test with glucose, insulin and C-peptide estimation).

    Time frame: Baseline and Final Visit.

  8. Change from Baseline in Inflammation Markers (high-sensitivity C-reactive protein, IL-6, vascular adhesion molecules (E-selectin, vascular cell adhesion molecule-1), monocyte chemotactic protein-1 and tumor necrosis factor-alpha).

    Time frame: Baseline and Weeks 12 and 24.

  9. Change from Baseline in Adipokines (adiponectin).

    Time frame: Baseline and Weeks 12 and 24.

  10. Change from Baseline in Oxidative Stress (maleic dialdehyde, ferric reducing antioxidant power and lipid hydroperoxide.

    Time frame: Baseline and Weeks 12 and 24.

  11. Urinary albumin excretion.

    Time frame: Weeks: 12 and 24.

08

Study locations

2 sites
  • Padova, Italy
  • Pisa, Italy
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2008
First posted
Oct 10, 2008
Start
Mar 2009
Primary completionActual
May 2011
CompletionActual
May 2011
Last update
Jul 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00770835
Lead sponsor
Takeda
First posted
Oct 10, 2008
Start date
Mar 2009
Primary completion
May 2011
Completion
May 2011
Last update
Jul 12, 2011

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Metformin

Start the discussion